Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bumetanide in children with Autism Spectrum Disorder
NCT03715153Phase 3Terminated
- Sponsor
- Servier
- Start
- Oct 2018
- Primary completion
- Oct 2021
- Countries
- 12
01
Overview
A Phase 3 trial of bumetanide in Autism Spectrum Disorder (ASD), sponsored by Servier. Started Oct 2018; status: terminated.
02
Drugs
bumetanide
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03715153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03715153.